Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 6/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6190226 | 0.94 | LMNA (0.69) | LMNAKMT2AIL4I1MAOBALDH1A1 | |
| SCHEMBL3993631 | 0.88 | LMNA (0.51) | LMNAKMT2AIL4I1MAOBMAOA | |
| SCHEMBL2253024 | 0.85 | IL4I1 (0.55) | LMNAKMT2AIL4I1MAOBMAOA | |
| SCHEMBL7054964 | 0.85 | MAOB (0.53) | LMNAKMT2AIL4I1MAOBMAOA | |
| SCHEMBL1481937 | 0.85 | PRSS1 (0.55) | LMNAIL4I1MAOBMAOAALDH1A1 | |
| SCHEMBL334537 | 0.85 | MAOB (0.53) | LMNAIL4I1MAOBMAOAALDH1A1 | |
| SCHEMBL3995446 | 0.85 | IL4I1 (0.45) | LMNAKMT2AIL4I1MAOBMAOA | |
| SCHEMBL10131961 | 0.84 | NOS1 (0.51) | LMNAKMT2AIL4I1MAOBALDH1A1 | |
| SCHEMBL7085241 | 0.84 | MEN1 (0.50) | LMNAKMT2AIL4I1MAOBMAOA | |
| SCHEMBL1437331 | 0.84 | IL4I1 (0.57) | LMNAKMT2AIL4I1MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505953-B2 | Temporary adhesive for production of semiconductor device, and adhesive support and production method of semiconductor device using the same | FUJIFILM CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9505953-B2 | Temporary adhesive for production of semiconductor device, and adhesive support and production method of semiconductor device using the same | FUJIFILM CORPORATION (JP) | 2016-11-29 | — | — | US | disclosed |
| US-20150184033-A1 | TEMPORARY ADHESIVE FOR PRODUCTION OF SEMICONDUCTOR DEVICE, AND ADHESIVE SUPPORT AND PRODUCTION METHOD OF SEMICONDUCTOR DEVICE USING THE SAME | FUJIFILM CORPORATION (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150184033-A1 | TEMPORARY ADHESIVE FOR PRODUCTION OF SEMICONDUCTOR DEVICE, AND ADHESIVE SUPPORT AND PRODUCTION METHOD OF SEMICONDUCTOR DEVICE USING THE SAME | FUJIFILM CORPORATION (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20100144872-A1 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation | BIOLIPOX AB | 2010-06-10 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-7264932-B2 | Nuclease inhibitor cocktail | APPLERA CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | AMBION, INC (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | AMBION, INC (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032418-A1 | Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same | RNASE1, RNASEH1, RNASEL | LMNA 1506/4885KMT2A 2728/4885IL4I1 2018/4885 |
| US-20100144872-A1 | New Methylenebisphenyl Compounds Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | LMNA 1200/4885KMT2A 4008/4885IL4I1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.